Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Meridian Bioscience, Inc.    VIVO

News SummaryMost relevantAll newsSector newsTweets

Meridian Bioscience : Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13/2018 | 03:36am CET

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Meridian Bioscience, Inc. (“Meridian Bioscience” or the “Company”) (NASDAQ: VIVO) securities between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”) Meridian Bioscience investors have until January 16, 2018 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Meridian Bioscience page on our website at www.glancylaw.com/case/meridian-bioscience-inc.

Investors suffering losses on their Meridian Bioscience investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to [email protected].

On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) issued a warning to Meridian that lead tests conducted by the Company’s subsidiary, Magellan Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to “results that are lower than the actual level of lead in the blood.” The FDA has recommended discontinuation of Magellan when testing with venous blood samples. On this news, Meridian shares fell over 9% on May 17, 2017. Then on May 25, 2017, Meridian’s Magellan Diagnostics announced a Class 1 recall of its LeadCare Plus and Ultra Testing Systems due to “inaccurate test results.”

On June 6, 2017 Meridian’s Magellan Diagnostics subsidiary expanded the recall to incorporate the Company’s LeadCare and LeadCare II testing systems. On this news, shares of Meridian traded as low as $13.40 per share.

The complaint alleges that throughout the class period Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant’s lead tests provide inaccurate results; and (2) consequently, Meridian’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Meridian Bioscience during the Class Period you may move the Court no later than January 16, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
04:51a MERIDIAN BIOSCIENCE INVESTIGATION IN : Kahn Swick & Foti, LLC Investigates the O..
01/19 Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Op..
01/16 MERIDIAN BIOSCIENCE, INC. : FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman..
01/15 MERIDIAN BIOSCIENCE, INC. : The Klein Law Firm Reminds Investors of Commencement..
01/13 MERIDIAN BIOSCIENCE : Glancy Prongay & Murray Reminds Investors of the January 1..
01/12 MERIDIAN BIOSCIENCE, INC. : UPCOMING DEADLINE: The Klein Law Firm Reminds Invest..
01/12 MERIDIAN BIOSCIENCE, INC. : Pomerantz Law Firm Investigates Claims On Behalf of ..
01/11 MERIDIAN BIOSCIENCE, INC. : Levi & Korsinsky, LLP Reminds Shareholders It Filed ..
01/10 MERIDIAN BIOSCIENCE, INC. : VIVO The Law Offices of Vincent Wong Notifies Invest..
01/10 VIVO Law Offices of Howard G. Smith Announces the Filing of a Securities Clas..
More news
News from SeekingAlpha
01/11 Becton, Dickinson gets Warning Letter after FDA inspection of New Jersey faci..
2017 Healthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novart..
2017 Meridian Bio registers $100M mixed shelf offering; shares off 1%
2017 HEALTHCARE DOGFIGHT : GlaxoSmithKline Regains Top By Gains In November As O&M & ..
2017 Meridian Bioscience declares $0.125 dividend
Financials ($)
Sales 2018 207 M
EBIT 2018 43,9 M
Net income 2018 27,1 M
Finance 2018 17,4 M
Yield 2018 3,30%
P/E ratio 2018 24,05
P/E ratio 2019 20,87
EV / Sales 2018 3,01x
EV / Sales 2019 2,84x
Capitalization 641 M
Duration : Period :
Meridian Bioscience, Inc. Technical Analysis Chart | VIVO | US5895841014 | 4-Traders
Technical analysis trends MERIDIAN BIOSCIENCE, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 7
Average target price 14,7 $
Spread / Average Target -3,2%
EPS Revisions
John P. Kenny Chief Executive Officer & Director
Richard L. Eberly President & Chief Commercial Officer
John A. Kraeutler Executive Chairman
Lawrence J. Baldini Executive VP & President-Global Operations
Melissa A. Lueke Chief Financial Officer, Secretary & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC6.64%117 321